Table 1 Sensitivity of UKF-NB-3 and UKF-NB-3rNutlin10 μM cells to a panel of established cytotoxic drugs indicated by the concentration that reduces cell viability by 50% (IC50a) indicated by MTT assay after a 5-day treatment period

From: Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells

 

IC50 (ng/mla)

  

UKF-NB-3 r Nutlin 10 μM

Drug

UKF-NB-3

After 7 passages of adaptation to nutlin-3

After 20 passages of adaptation to nutlin-3

After 7 passages of adaptation to nutlin-3 plus 20 passages cultivation in the absence of nutlin-3

Nutlin-3a

1.01±0.11

35.09±4.21

38.71±5.60

34.88±6.75

Vincristine

0.29±0.04

1.41±0.33

1.32±0.26

1.36±0.20

Cisplatin

108.77±22.32

293.02±31.63

342.52±42.71

280.14±24.83

Actinomycin D

0.20±0.05

0.59±0.18

0.70±0.24

0.61±0.18

Melphalan

178.69±52.47

439.56±46.71

451.02±51.31

426.22±44.89

Paclitaxel

1.33±0.31

3.48±0.42

3.25±0.18

3.09±0.41

Doxorubicin

9.18±1.64

24.21±4.03

28.41±3.97

29.97±5.86

Topotecan

0.90±0.06

3.95±1.09

4.22±0.85

3.77±0.68

  1. aAll concentrations are expressed in ng/ml, except nutlin-3 concentrations that are expressed in μM
Back to article page